United States Patent 5,372,808: Claims and Patent Landscape Analysis
United States Patent 5,372,808 (the '808 patent) relates to a drug delivery system primarily designed for sustained release of pharmacologically active compounds. This analysis evaluates the scope of its claims, assesses potential overlaps with existing patents, and examines its influence within the competitive landscape.
What Are the Key Claims of Patent 5,372,808?
The '808 patent, issued in 1994 to BICAR Corporation, claims a pharmaceutical formulation involving a specific matrix composition for controlled drug release. Its primary claims focus on:
-
A sustained-release oral dosage form comprising a matrix with a specific polymeric component.
-
The polymer matrix includes a hydrophilic polymer (e.g., hydroxymethylcellulose) combined with an insoluble filler.
-
A method of manufacturing the dosage form involving specific mixing and compression steps.
-
The controlled release characteristics demonstrated through in vitro dissolution profiles over 12-24 hours.
The core innovation centers on extending drug release via a matrix that maintains consistent release kinetics and resists premature disintegration.
Claim Scope Breakdown
| Claim Element |
Description |
Impact on Scope |
| Polymer composition |
Hydrophilic polymer, insoluble filler |
Defines formulation boundaries |
| Method of preparation |
Mixing, compression, curing |
Restricts claims to specified manufacturing steps |
| Release profile |
Sustained release over 12-24 hours |
Core functional characteristic |
| Compatibility with multiple drugs |
Stated generally, not drug-specific |
Broadens applicability |
The claims are relatively narrow in structure but broad in application, covering a class of formulations with certain release characteristics.
How does '808 pose within the patent landscape?
The '808 patent sits amid a dense field of controlled-release patents filed in the late 1980s and early 1990s. Its unique features include specific polymer combinations and manufacturing processes.
Overlapping Patents and Prior Art
-
Prior art references such as U.S. Patent 4,195,039 (by Fischel et al., 1980), describe similar hydrophilic matrices for sustained release, focusing on cellulose derivatives.
-
Likely exclusion or obviousness arguments could emerge concerning the polymer composition, as broad language encompasses earlier formulations.
-
Similar patents include US 4,472,235 (Seeger et al.), which involves controlled-release matrices with hydrophilic polymers, pre-dating the '808 patent.
Innovation and Patentable Subject Matter
-
The patent's novelty hinges on specific combinations—such as the insoluble filler and particular manufacturing steps—that differ from prior formulations.
-
The inclusion of the curing process and the dissolution profile claims offer potentially patentable elements, provided they are non-obvious and adequately supported.
Patent Status and Litigation
-
The patent expired in 2011, after 17 years from issue, due to maintenance fee lapses or possible abandonment.
-
There are no known major litigations or licensing disputes associated with the '808 patent.
The Commercial and Research Implication Landscape
-
The patent's expiration broadens market access, leading to an increase in generic formulations.
-
Key competitors have developed alternative sustained-release technologies, such as matrix tablets employing different polymers (e.g., polyvinyl acetate).
-
Numerous follow-on patents cite the '808 patent, indicating its influence as prior art but also potential pathways for designing around it.
Limitations and Critical Observations
-
The claims' reliance on specific polymer combinations limits the patent's enforceability broadly against formulations employing different matrices.
-
The patent's intermediate datedness implies that more modern polymer systems (e.g., osmotic pump systems) fall outside its scope.
-
The patent landscape shows a shift toward complex delivery systems that depart from simple hydrophilic matrices.
Key Takeaways
-
The '808 patent claims a specific sustained-release matrix formulation with defined manufacturing steps, bearing narrow but defensible scope during its term.
-
It faced substantial prior art challenges that could question novelty and non-obviousness.
-
Its expiration has led to increased generic competition and a proliferation of alternative sustained-release platforms.
-
Patent landscape analysis underscores the importance of formulation specifics and process claims in establishing patentability within drug delivery technologies.
-
The landscape emphasizes the trend towards more sophisticated, multi-mechanism delivery systems departing from hydrophilic matrices.
FAQs
1. Does the expiration of the '808 patent open the market entirely to generics?
Yes, the patent's expiry allows generic manufacturers to produce similar sustained-release formulations without infringement.
2. Can a new formulation still avoid infringement if based on the '808 patent?
Yes. Designing around claims by changing polymer types, manufacturing steps, or release mechanisms can circumvent the patent.
3. Are there any active litigations or licensing deals associated with the '808 patent?
No; the patent has been inactive since it expired, with no recent legal proceedings known.
4. How does the '808 patent compare with newer controlled-release patents?
It is narrower, focusing on a specific matrix formulation, whereas newer patents involve complex delivery systems like osmotic pumps or multiparticulate formulations.
5. What strategic implications does the patent landscape offer for R&D?
Innovators should explore alternative mechanisms and formulations that do not fall within the scope of existing patents like the '808 or its successors.
References
[1] Fischel, E., et al. (1980). Controlled release devices. U.S. Patent 4,195,039.
[2] Seeger, R., et al. (1984). Controlled-release matrix systems. U.S. Patent 4,472,235.
[3] U.S. Patent and Trademark Office (USPTO). (1994). Patent No. 5,372,808.
